溃疡性结肠炎诱导和维持治疗期间戈利木单抗血清浓度的治疗阈值:GO-LEVEL研究结果
GO-LEVEL为开放标签IV期研究,纳入起始戈利木单抗的溃疡性结肠炎前瞻队列及维持治疗横断面队列。诱导队列39例中15例(38%)第6周达临床-生化缓解,缓解者中位谷浓度5.0 μg/mL高于未缓解者3.1 μg/mL(P=0.03),ROC曲线确定3.8 μg/mL为最佳阈值。维持队列63例中31例(49%)达联合缓解,缓解者中位浓度2.9 μg/mL高于未缓解者2.1 μg/mL(P=0.01),ROC确定2.4 μg/mL为最佳阈值。
要点
- 诱导队列第6周联合临床-生化缓解者中位戈利木单抗谷浓度5.0 μg/mL,未缓解者3.1 μg/mL(P=0.03)。
- 诱导期ROC曲线确定3.8 μg/mL为最佳阈值(灵敏度0.71,特异度0.65,AUC 0.72)。
- 维持期联合缓解者中位浓度2.9 μg/mL,未缓解者2.1 μg/mL(P=0.01),ROC最佳阈值2.4 μg/mL。
核心结论
- GO-LEVEL(NCT03124121)为戈利木单抗暴露-反应关系提供了进一步证据。
- 临床医生可考虑使用治疗药物监测优化戈利木单抗给药,以期达到作者建议的诱导第6周3.8 μg/mL和维持期2.4 μg/mL的治疗阈值。
研究设计与样本
- GO-LEVEL为开放标签IV期研究,包含起始戈利木单抗的溃疡性结肠炎前瞻队列和接受维持治疗的横断面队列。
- 活动性溃疡性结肠炎诱导队列(SCCAI>5且FC>59μg/g或CRP>5mg/L或Mayo内镜疾病活动度2或3)在第6、10、14周评估。
- 维持治疗患者在 flare 时或缓解期招募。
- 诱导队列39例,维持队列63例。
- 血清戈利木单抗浓度采用市售ELISA(LISATRACKER,Theradiag)测定。
主要发现
- 诱导队列39例中15例(38%)在第6周达到联合临床-生化缓解。
- 诱导队列联合缓解者中位血清戈利木单抗浓度5.0 μg/mL vs 未缓解者3.1 μg/mL(P=0.03)。
- 诱导期ROC曲线分析显示3.8 μg/mL为最佳阈值(灵敏度0.71,特异度0.65,AUC 0.72,PPV 0.59,NPV 0.79)。
- 维持队列63例中31例(49%)达联合缓解,32例(51%)未达。
- 维持队列联合缓解者中位浓度2.9 μg/mL vs 未缓解者2.1 μg/mL(P=0.01);ROC曲线显示2.4 μg/mL为最佳阈值(灵敏度0.68,特异度0.66,AUC 0.68,PPV 0.65,NPV 0.66)。
关键数值与推荐
- 联合临床-生化缓解定义为SCCAI≤2且FC<250μg/g。
- 活动性溃疡性结肠炎定义为SCCAI>5且FC>59μg/g或CRP>5mg/L或Mayo内镜疾病活动度2或3。
临床怎么用
- 作者认为临床医生可考虑使用治疗药物监测优化戈利木单抗给药,以期达到诱导第6周3.8 μg/mL和维持期2.4 μg/mL的阈值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Significant associations between serum golimumab concentrations and favourable outcomes have been observed during both induction and maintenance therapy in ulcerative colitis (UC). However, data regarding optimal therapeutic serum golimumab concentration thresholds are limited. AIMS: To identify optimal serum golimumab concentration thresholds during induction and maintenance treatment with golimumab. METHODS: GO-LEVEL was an open label, phase IV study that included a prospective cohort of UC patients commencing golimumab, as well as a cross-sectional cohort receiving maintenance treatment. Patients commencing induction for active UC (defined as a simple clinical colitis activity index [SCCAI] >5 in addition to a raised faecal calprotectin [FC] >59μg/g or, raised C-reactive protein [CRP] [>5mg/L] or, Mayo endoscopic disease activity 2 or 3) were evaluated at weeks 6, 10 and 14. Patients receiving maintenance therapy were recruited either at the point of flare or during remission. Combined clinical-biochemical remission was defined as SCCAI ≤2 and FC <250μg/g. Serum golimumab concentrations were measured using a commercially available ELISA (LISATRACKER, Theradiag). RESULTS: Thirty-nine patients were included in the induction cohort, of whom 15 (38%) achieved combined clinical-biochemical remission at week 6. The median serum golimumab concentration of those in combined clinical-biochemical remission was significantly higher than those who were not (5.0 vs 3.1 μg/mL, respectively, P = 0.03). Receiver operating characteristic (ROC) curve analysis demonstrated 3.8 μg/mL as the optimal threshold (sensitivity 0.71, specificity 0.65, area under curve [AUC] 0.72, positive predictive value [PPV] 0.59 and negative predictive value [NPV] 0.79). Sixty-three patients were included in the maintenance cohort; 31 (49%) were in combined remission, 32 (51%) were not. The median serum golimumab concentration of those in combined remission was significantly higher (2.9 vs 2.1 μg/mL, respectively, P = 0.01). ROC curve analysis demonstrated 2.4 μg/mL as the optimal threshold (sensitivity 0.68, specificity 0.66, AUC 0.68, PPV 0.65 and NPV 0.66). CONCLUSIONS: GO-LEVEL (NCT03124121) offers further evidence regarding golimumab's exposure-response relationship. Clinicians may consider using therapeutic drug monitoring to optimise golimumab dosing aiming to achieve our suggested therapeutic thresholds of 3.8 μg/mL at week 6 and 2.4 μg/mL during maintenance.
引用
- Samaan MA, Cunningham G, Tamilarasan AG, et al. Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study. Aliment Pharmacol Ther. 2020. PMID: 32506695. doi:10.1111/apt.15808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。